18th Jan 2017 12:09
LONDON (Alliance News) - Summit Therapeutics PLC on Wednesday said that it has appointed David Roblin to a new non-board role of chief operating officer and president of research and development.
In this role, Roblin will lead research and development and commercial functions to support the development of Summit's Duchenne Muscular Dystrophy and Clostridium difficile infection programmes.
Roblin has been acting as research and development adviser to Summit since 2014, and will take up the new role on an interim basis in April, before becoming full-time in June 2017.
Shares in Summit were up 3.5% at 164.00 pence Wednesday afternoon.
By Hana Stewart-Smith; [email protected]; @HanaSSAllNews
Copyright 2017 Alliance News Limited. All Rights Reserved.
Related Shares:
SUMM.L